HGS
Basic information
Region (hg38): 17:81683326-81703138
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HGS gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 6 | |||||
missense | 38 | 42 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 9 | |||||
Total | 0 | 1 | 43 | 7 | 6 |
Variants in HGS
This is a list of pathogenic ClinVar variants found in the HGS region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-81683555-G-T | not specified | Uncertain significance (Nov 29, 2021) | ||
17-81683716-G-A | not specified | Uncertain significance (Feb 05, 2024) | ||
17-81683735-C-G | not specified | Uncertain significance (Mar 25, 2024) | ||
17-81683746-A-G | not specified | Uncertain significance (Feb 15, 2023) | ||
17-81683756-C-T | not specified | Uncertain significance (Dec 18, 2023) | ||
17-81683773-G-T | not specified | Uncertain significance (Aug 02, 2021) | ||
17-81683794-C-A | Childhood-onset schizophrenia | Likely pathogenic (Jan 01, 2014) | ||
17-81686350-A-C | not specified | Uncertain significance (Aug 02, 2023) | ||
17-81686994-C-T | Benign (Jul 06, 2018) | |||
17-81687042-C-T | not specified | Uncertain significance (Feb 10, 2022) | ||
17-81687055-C-G | not specified | Uncertain significance (Nov 09, 2023) | ||
17-81688716-G-T | not specified | Uncertain significance (Jun 27, 2023) | ||
17-81688776-G-A | not specified | Uncertain significance (Dec 20, 2023) | ||
17-81690173-T-C | Likely benign (Jun 04, 2018) | |||
17-81691447-C-T | Uncertain significance (Apr 01, 2023) | |||
17-81693538-T-G | not specified | Uncertain significance (Sep 12, 2023) | ||
17-81693549-T-C | not specified | Uncertain significance (May 30, 2023) | ||
17-81693553-T-C | not specified | Uncertain significance (Mar 01, 2024) | ||
17-81693560-C-A | not specified | Uncertain significance (Aug 17, 2021) | ||
17-81693564-C-A | not specified | Uncertain significance (Dec 27, 2023) | ||
17-81693571-A-C | not specified | Uncertain significance (Jan 03, 2024) | ||
17-81693574-A-C | not specified | Uncertain significance (Jan 20, 2023) | ||
17-81693579-C-G | Likely benign (Jul 20, 2018) | |||
17-81693660-C-G | not specified | Uncertain significance (Aug 16, 2022) | ||
17-81693880-C-T | not specified | Uncertain significance (Sep 14, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HGS | protein_coding | protein_coding | ENST00000329138 | 22 | 19813 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00636 | 0.994 | 125717 | 0 | 29 | 125746 | 0.000115 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.28 | 404 | 484 | 0.836 | 0.0000314 | 5004 |
Missense in Polyphen | 226 | 281.32 | 0.80334 | 2876 | ||
Synonymous | -2.69 | 269 | 218 | 1.23 | 0.0000167 | 1493 |
Loss of Function | 4.45 | 13 | 45.4 | 0.287 | 0.00000203 | 516 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000420 | 0.000419 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000110 | 0.000109 |
Finnish | 0.0000926 | 0.0000924 |
European (Non-Finnish) | 0.0000710 | 0.0000703 |
Middle Eastern | 0.000110 | 0.000109 |
South Asian | 0.0000655 | 0.0000653 |
Other | 0.000332 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in intracellular signal transduction mediated by cytokines and growth factors. When associated with STAM, it suppresses DNA signaling upon stimulation by IL-2 and GM-CSF. Could be a direct effector of PI3-kinase in vesicular pathway via early endosomes and may regulate trafficking to early and late endosomes by recruiting clathrin. May concentrate ubiquitinated receptors within clathrin-coated regions. Involved in down- regulation of receptor tyrosine kinase via multivesicular body (MVBs) when complexed with STAM (ESCRT-0 complex). The ESCRT-0 complex binds ubiquitin and acts as sorting machinery that recognizes ubiquitinated receptors and transfers them to further sequential lysosomal sorting/trafficking processes. May contribute to the efficient recruitment of SMADs to the activin receptor complex. Involved in receptor recycling via its association with the CART complex, a multiprotein complex required for efficient transferrin receptor recycling but not for EGFR degradation.;
- Pathway
- Endocytosis - Homo sapiens (human);Phagosome - Homo sapiens (human);TGF-Ncore;TGF-beta Signaling Pathway;VEGFA-VEGFR2 Signaling Pathway;EGF-EGFR Signaling Pathway;Lysosome Vesicle Biogenesis;Clathrin derived vesicle budding;Disease;trans-Golgi Network Vesicle Budding;Signal Transduction;Vesicle-mediated transport;Membrane Trafficking;Post-translational protein modification;Endosomal Sorting Complex Required For Transport (ESCRT);Metabolism of proteins;TCR;Infectious disease;Fibroblast growth factor-1;EGFR downregulation;Signaling by EGFR;Clathrin-mediated endocytosis;TGF_beta_Receptor;EGFR1;CXCR4-mediated signaling events;Ub-specific processing proteases;Posttranslational regulation of adherens junction stability and dissassembly;Deubiquitination;Cargo recognition for clathrin-mediated endocytosis;Negative regulation of MET activity;Signaling by MET;Signaling by Receptor Tyrosine Kinases;Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met);Internalization of ErbB1;Signaling events mediated by VEGFR1 and VEGFR2;InlB-mediated entry of Listeria monocytogenes into host cell;Listeria monocytogenes entry into host cells
(Consensus)
Recessive Scores
- pRec
- 0.383
Intolerance Scores
- loftool
- 0.445
- rvis_EVS
- -1.5
- rvis_percentile_EVS
- 3.6
Haploinsufficiency Scores
- pHI
- 0.440
- hipred
- Y
- hipred_score
- 0.695
- ghis
- 0.593
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- K
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.991
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hgs
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); muscle phenotype; cellular phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- protein targeting to lysosome;signal transduction;negative regulation of cell population proliferation;membrane invagination;positive regulation of gene expression;negative regulation of platelet-derived growth factor receptor signaling pathway;endosomal transport;macroautophagy;negative regulation of angiogenesis;negative regulation of vascular endothelial growth factor receptor signaling pathway;multivesicular body assembly;negative regulation of epidermal growth factor receptor signaling pathway;regulation of protein catabolic process;regulation of MAP kinase activity;negative regulation of JAK-STAT cascade;membrane organization;protein localization to membrane;positive regulation of exosomal secretion
- Cellular component
- lysosome;endosome;early endosome;cytosol;early endosome membrane;multivesicular body membrane;ESCRT-0 complex;intracellular membrane-bounded organelle;extracellular exosome
- Molecular function
- protein binding;protein domain specific binding;ubiquitin-like protein ligase binding;metal ion binding